NCT06002503View on ClinicalTrials.gov

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Vaccine Reaction
Interventions
DRUG

Venezuelan Equine Encephalitis DNA Vaccine

Venezuelan Equine Encephalitis DNA Vaccine Candidate

DEVICE

PharmaJet Stratis Needle-free Injection System

Intramuscular Needle-free Injection System (Jet Injector)

DEVICE

PharmaJet Tropis Needle-free Injection System

Intradermal Needle-free Injection System (Jet Injector)

Trial Locations (1)

45246

Velocity Clinical Research, Cincinnati

Sponsors

Lead Sponsor

PharmaJet, Inc.
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

PharmaJet, Inc.

INDUSTRY